| Recruiting | An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome NCT05066217 | Epygenix | Phase 3 |
| Recruiting | Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY NCT05485831 | Jazz Pharmaceuticals | — |
| Recruiting | BMB-101 in Absence Epilepsy and DEE NCT06401538 | Bright Minds Biosciences Pty Ltd | Phase 2 |
| Active Not Recruiting | Pallidothalamic Tracts Electrical Stimulation for Lennox-Gastaut Syndrome NCT06464653 | Liankun_Ren | N/A |
| Completed | Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy NCT05626634 | Longboard Pharmaceuticals | Phase 2 |
| Active Not Recruiting | RNS System LGS Feasibility Study NCT05339126 | NeuroPace | Phase 2 |
| Recruiting | Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Chi NCT05219617 | SK Life Science, Inc. | Phase 3 |
| Recruiting | Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut NCT05374824 | Ann & Robert H Lurie Children's Hospital of Chicago | — |
| Completed | Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies NCT05364021 | Longboard Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Sol NCT05044819 | Jazz Pharmaceuticals | Phase 4 |
| Withdrawn | Investigation of Cognitive Outcomes With Cannabidiol Oral Solution NCT04133480 | Jazz Pharmaceuticals | Phase 4 |
| Unknown | Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome NCT04611438 | Yonsei University | Phase 3 |
| Completed | Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome NCT04062981 | SK Life Science, Inc. | Phase 1 |
| Completed | A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children an NCT03936777 | Zogenix, Inc. | Phase 3 |
| Terminated | Long-term Cardiac Monitoring in Epilepsy NCT03955432 | Northwell Health | N/A |
| Completed | Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome NCT03731715 | SK Life Science, Inc. | Phase 1 |
| Completed | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, a NCT03650452 | Takeda | Phase 2 |
| Withdrawn | Turmeric as Treatment in Epilepsy NCT03254680 | NYU Langone Health | N/A |
| Completed | A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Le NCT03467113 | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | Phase 1 |
| Withdrawn | Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled NCT02318537 | INSYS Therapeutics Inc | Phase 3 |
| Completed | A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy NCT03355209 | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | Phase 3 |
| Terminated | The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy NCT02815540 | Gillette Children's Specialty Healthcare | Phase 1 / Phase 2 |
| Unknown | Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome NCT02632149 | Beijing Pins Medical Co., Ltd | EARLY_Phase 1 |
| Withdrawn | The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy NCT02910297 | Gillette Children's Specialty Healthcare | — |
| Unknown | Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy NCT02655198 | KU Leuven | Phase 2 |
| Completed | An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut NCT02224573 | GW Research Ltd | Phase 3 |
| Completed | Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults NCT02224560 | Jazz Pharmaceuticals | Phase 3 |
| Completed | A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Se NCT02224690 | Jazz Pharmaceuticals | Phase 3 |
| Completed | Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Sy NCT02175173 | Eisai Co., Ltd. | — |
| Withdrawn | Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects NCT01370486 | Institution de Lavigny | Phase 4 |
| Completed | Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequat NCT01405053 | Eisai Inc. | Phase 3 |
| Completed | A Long Term Extension Study of E2080 in Lennox-Gastaut Patients NCT01151540 | Eisai Co., Ltd. | Phase 3 |
| Completed | Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilo NCT02731300 | Khon Kaen University | Phase 4 |
| Completed | A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080 NCT01146951 | Eisai Limited | Phase 3 |
| Completed | European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS) NCT01991041 | Eisai Limited | — |
| Completed | Epilepsy Phenome/Genome Project NCT00552045 | University of California, San Francisco | — |
| Completed | Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome NCT01160770 | Lundbeck LLC | Phase 3 |
| Completed | Ketogenic Diet for Child Epilepsy and Seizure Control NCT00004729 | National Institute of Neurological Disorders and Stroke (NINDS) | N/A |
| Completed | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome NCT00004776 | National Center for Research Resources (NCRR) | Phase 3 |
| Available | An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303 NCT03778424 | Eisai Inc. | — |
| Available | Intermediate-Size Expanded Access Protocol (EAP) for LP352 NCT06149663 | Longboard Pharmaceuticals | — |
| No Longer Available | An Extended Access Program (EAP) for Perampanel NCT02307578 | Eisai Inc. | — |